Endocrine-Related Cancer

Article	Citations
Acknowledgement to reviewers	104
Survival following resection of 10,244 lung neuroendocrine tumours: a population study	92
Refining long-term surveillance requirements in patients with differentiated thyroid cancer	62
ERRATUM: Roles of the HOXA10 gene during castrate-resistant prostate cancer progression	53
Chemokines with CXC motif and their receptors in neuroendocrine neoplasms	49
Clinical presentation of bone metastases in neuroendocrine tumors: a retrospective cohort study	46
Defining aging-associated factors that increase susceptibility to prostate cancer	45
Acknowledgement to reviewers	44
Prognostic of recurrence and survival in poorly differentiated thyroid cancer	33
Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells	33
Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients	32
Targeting growth hormone in cancer: future perspectives	32
Сytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas	31
Identifying metastatic renal cell carcinoma in thyroid fine-needle aspirates by molecular testing	28
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs	27
Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications	27
Update on the genetics of paragangliomas	27
Peptide receptor radionuclide therapy in malignant insulinoma	26
Differential activity of specific inhibitors of transcription regulating cyclin-dependent kinases in thyroid cancer cells	26
FAM64A contributes to ovarian cancer proliferation and metastasis by suppressing TWIST1 ubiquitination and degradation	25
CORRIGENDUM: GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts	24
The genetic changes in 11p15.5-related pheochromocytomas and paragangliomas	24
Metabolically active brown adipose tissue in PPGL: an observational cohort study	23
Impact of sex hormones on development and progression in NEN: a new therapeutic target?	23
MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells	23

Genistein induces endocrine resistance in human breast cancer by suppressing H3K27 trimethylation	22
Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet	21
CCL2 expression predicts clinical outcomes and regulates E-cadherin and angiogenesis in pituitary tumours	21
Two miRNAs enriched in plasma extracellular vesicles are potential biomarkers for thyroid cancer	20
Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma	18
Rising incidence of follicular thyroid carcinoma and oncocytic carcinoma of the thyroid in Australia	18
Whole-exome sequencing of rectal neuroendocrine tumors	17
lncRNA DIRC3 regulates invasiveness and insulin-like growth factor signaling in thyroid cancer cells	17
Gender-affirming care and endocrine-related cancers	16
Bone metastasis in endocrine-related cancer: unravelling invasion and destruction	15
Effect of TSH levels during active surveillance of PTMC according to age	15
Distortion in transmission of pathogenic SDHB- and SDHD-mutated alleles from parent to offspring	15
Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective	15
Long-term survival of metastatic small intestine neuroendocrine tumors: a meta-analysis	15
RET signalling in the pituitary: a double-edged sword for differentiation, apoptosis and therapeutic strategies in acromegaly	15
Immunotherapy for endocrine tumours: a clinician’s perspective	14
Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study	14
Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen	14
ThyroidPrint®: clinical utility for indeterminate thyroid cytology	14
Steroid profile in patients with breast cancer and in mice treated with mifepristone	13
Embryonic stem cell factor FOXD3 (Genesis) defects in gastrointestinal stromal tumors	13
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms	13
Genetic variants of glucose metabolism and exposure to smoking in African American breast cancer	13
Inhibition of GATA2 in prostate cancer by a clinically available small molecule	12
The role of the tumor microenvironment in papillary thyroid microcarcinoma nodal metastasis	12
Clinical features of plurihormonal pituitary adenoma subtypes	12
Acknowledgement to reviewers	12
From bench to bedside in the sella: translational developments in pituitary tumour genetics	12
Exploring the tumor suppressor role of RIN1 in familial thyroid carcinoma	12
Acknowledgement to reviewers	12
Exploring stem cell biology in pituitary tumors and derived organoids	12
Subgroup analysis of steadily increased trends in medullary thyroid carcinoma incidence and mortality in the USA, 2000–2020: a population-based retrospective cohort study	11
Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review	11
Ampullary composite gangliocytoma/neuroma and neuroendocrine tumor management	11
Mammary gland development and EDC-driven cancer susceptibility in mesenchymal ERα-knockout mice	11
Systems biology successes and areas for opportunity in prostate cancer	11
New therapeutic opportunities for women with low-grade serous ovarian cancer	11
In vivo and in vitro analysis of functional effects of the SDHD H50R variant	11
Genetic disorders and insulinoma/glucagonoma	11
Plasma metabolomics for the preoperative diagnosis of parathyroid carcinoma	11
Two distinct classes of thymic tumors in patients with MEN1 show LOH at the MEN1 locus	11
Clinical Outcomes of Malignant Pleural Effusion in Patients with Lung Metastases from Differentiated Thyroid Cancer	10
Spectrum and carcinogenic properties of thyroglobulin gene fusions in thyroid	10
Diagnosis and management of parathyroid carcinoma: a state-of-the-art review	10
Cancer in Ecuadorian subjects with Laron syndrome (ELS)	10
Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity	10
Insights on epidemiology, morbidity and mortality of Cushing’s disease in Northern Ireland	10
Non-pituitary GH regulation of the tissue microenvironment	9
COL12A1 as a prognostic biomarker links immunotherapy response in breast cancer	9
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal	9

Genetic variants and down-regulation of CACNA1H in pheochromocytoma	9
Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane	9
Cutoff value of thyroglobulin in needle aspirates for screening neck masses of thyroid carcinoma	9
Deiodinases in thyroid tumorigenesis	9
In memoriam: Charis Eng MD PhD (1962–2024)	9
Reduced MHC class II expression in medullary thyroid cancer identifies patients with poor prognosis	9
Surrogate molecular classification of LAR breast cancer in routine workflow	9
Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort	9
Beyond the three P’s: adrenal involvement in MEN1	9
Sexual dimorphism in thyroid cancer: evidence from preclinical studies	9
International symposium on pheochromocytoma: an event of dedicated healthcare professionals and researchers striving for better patient outcomes	9
miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2	9
Targeting anti-apoptosis as a therapeutic strategy in neuroendocrine neoplasms	8
Tumor suppressor gene ARMC5 controls adrenal redox state through NRF1 turnover	8
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading	8
Management of high-grade neuroendocrine neoplasms: impact of functional imaging	8
Promoter mutation-independent TERT expression is related to the immune-enriched milieu in papillary thyroid cancer	8
Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center	8
MicroRNAs as regulators of tumor metabolism	8
Mitochondrial dynamics and oxidative phosphorylation as critical targets in cancer	8
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma	8
Precocious puberty due to intracranial germ cell tumors: a case–control study	8
Genotype-specific development of MEN 2 constituent components in 683 RET carriers	8
The science behind the relations among cancer, height, growth patterns, and growth hormone axis	8
Limited value of genetic profiling in guiding radioiodine therapy for metastatic differentiated thyroid cancer	8
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms	8
MEN1 silencing triggers the dysregulation of mTORC1 and MYC pathways in ER+ breast cancer cells	7
Risk factors for intraoperative complications in pheochromocytomas	7
Endocrine cancer trends 1990–2021: global disparities and health inequalities	7
The role of delta-like non-canonical Notch ligand 1 (DLK1) in cancer	7
Insulinomatosis: new aspects	7
Exploring chromosomal instability and clonal heterogeneity in breast cancer	7
DNA methylation is a comprehensive marker for pediatric adrenocortical tumors	7
Reciprocal cancer risks between thyroid and breast cancer: a systematic review and meta-analysis	7
Association of serum steroids with survival in metastatic hormone-sensitive prostate cancer	7
Adjuvant and neoadjuvant therapy with cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic revie	7
Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma	7
A clinically applicable molecular classification of oncocytic cell thyroid nodules	7
Patient-reported burden associated with pheochromocytoma/paraganglioma diagnosis	7
Unregulated LDL cholesterol uptake is detrimental to breast cancer cells	7
Inflammation-based score in pediatric adrenocortical carcinoma	6
Predictors of cancer in patients with endogenous Cushing’s syndrome	6
Role of GDH and PARP inhibitors as novel treatments for SDHB-deficient PPGLs	6
Insulin-like growth factor-1 receptor crosstalk with integrins, cadherins, and the tumor microenvironment: sticking points in understanding IGF1R function in cancer	6
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer	6
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study	6
SYT7 plays a role in promoting thyroid cancer by mediating HMGB3 ubiquitination	6
Pathological features in non-neoplastic congenital and adult hyperinsulinism: from nesidioblastosis to current terminology and understanding	6
A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy	6
Clinicopathological features and outcomes of thyroid nodules with EIF1AX mutations	6
TLR4 inhibition suppresses growth in oestrogen-induced prolactinoma models	6
Management of advanced high grade gastro-enteropancreatic neuroendocrine neoplasms (GEP-NENs): comprehensive review of the current literature	6
Multimodal treatment for resectable neuroendocrine carcinoma of the cervix	6
Autophagic blockade potentiates anlotinib-mediated ferroptosis in anaplastic thyroid cancer	6
Association of DNA methylation with steroidogenic enzymes in Cushing’s adenoma	6
Multivariable model versus AJCC staging system: cancer-specific survival predictions in adrenocortical carcinoma	6
Long non-coding RNA MFSD4A-AS1 promotes lymphangiogenesis and lymphatic metastasis of papillary thyroid cancer	5
Mammary carcinoma in aged gerbil mothers after endocrine disruption in pregnancy and lactation	5
Clinicopathologic features of thyroid nodules with PTEN mutations on preoperative testing	5
Neuropilin 2 and soluble neuropilin 2 in neuroendocrine neoplasms	5
ERRATUM: The role of oestrogen receptor α in human thyroid cancer: contributions from coregulatory proteins and the tyrosine kinase receptor HER2	5
Pituitary tumor-transforming gene 1 and endocrine cancers: an up-to-date review through history, current insights and future perspectives	5
New drug delivery strategies targeting the GnRH receptor in breast and other cancers	5
Regulation of epinephrine biosynthesis in HRAS-mutant paragangliomas	5
Therapy-related myeloid neoplasms in 177Lu-DOTATATE treated neuroendocrine tumor patients: how great is the risk?	5
ERRATUM: Mutational landscape of non-functional adrenocortical adenomas	5
Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome	5
Progress and challenges in experimental models for pheochromocytoma and paraganglioma	5
Glycemic disorders in patients with pheochromocytomas and sympathetic paragangliomas	5
Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care	4
Why do we continue to have an incomplete understanding of estrogen receptor(s) actions in cancer systems?	4
Development and validation of long-acting recombinant human TSH using SAFA technology	4
Netrin-DCC Inhibition Suppresses Neuroendocrine Neoplasms Growth in vivo	4
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study	4
Nuclear and mitochondrial DNA alterations in pheochromocytomas and paragangliomas, and their potential treatment	4
Pregnancy-associated breast cancer: the influence of gestational age	4
Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells	4
An update on genetically engineered mouse models of pancreatic neuroendocrine neoplasms	4
Mechanisms of resistance to RET-directed therapies	4
Autocrine/paracrine growth hormone in cancer progression	4

Association between pembrolizumab-related thyroid adverse events and outcomes in early-stage triple-negative breast cancer patients	4
Phenotype of pheochromocytoma and paraganglioma by germline mutation: a Korean multicenter study	4
Improved and individualized approach to adrenal surgery	4
Impact of sex on treatment decisions and outcome in patients with neuroendocrine neoplasms	4
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study	4
Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma	4
Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer	4
β-Catenin activation and illicit receptor expression in adrenocortical cells	4
The role of membrane mucin MUC4 in breast cancer metastasis	4
Prognostic significance of hyperammonemia in neuroendocrine neoplasm patients with liver metastases	4
AGO2 protein: a key enzyme in the miRNA pathway as a novel biomarker in adrenocortical carcinoma	4
Developmental role of PHD2 in the pathogenesis of pseudohypoxic pheochromocytoma	4
Second primary cancers and survival among neuroendocrine tumor patients	4
The aggressiveness of succinate dehydrogenase subunit B-deficient chromaffin cells is reduced when their bioelectrical properties are restored by glibenclamide	4
NIFTPs may be reclassified not only from FVPTCs but also from follicular adenomas	4
The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas	4
Heme-oxygenase-1: a key player in thyroid carcinoma development	4
Core needle biopsy in pheochromocytoma/paraganglioma: should it be considered?	4
Therapeutic inhibition of ATR in differentiated thyroid cancer	4
Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN	4
FT3 and FT3/FT4 ratio are decreased and not compensated by levothyroxine treatment in TKI-treated thyroid cancer patients	3
Prognostic value of the Weiss and Wieneke (AFIP) scoring systems in pediatric ACC – a mini review	3
Reappraisal of BRAFK601E-positive thyroid tumors in the NIFTP era	3
The role of vitamin D in breast cancer risk and progression	3
Oxygen regulates proliferation and phenotype in the RS0 SDH-deficient pheochromocytoma cell line	3
Growth hormone and radiation therapy: friend, foe, or both?	3
Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients	3
Expression and clinical significance of VISTA and PD-L1 in adrenocortical carcinoma	3
Liquid biopsies in thyroid cancers: a systematic review and meta-analysis	3
Aggressive versus indolent insulinomas: new clinicopathological insights	3
Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial	3
Clinicopathological characteristics associated with the prognosis of recurrent gonadotroph tumors	3
Mannose enhances anti-tumor effect of PLX4032 in anaplastic thyroid cancer	3
Vandetanib downregulates type 2 deiodinase in fibro/adipogenic progenitors	3
One hundred years after the discovery of insulin and glucagon: the history of tumors and hyperplasias that hypersecrete these hormones	3